To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomi… (NCT07291921) | Clinical Trial Compass
RecruitingNot Applicable
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
China100 participantsStarted 2025-05-08
Plain-language summary
This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS), to establish a novel multidimensional approach for noninvasive postoperative recurrence monitoring in lung cancer using artificial intelligence algorithms. The goal is to develop a new noninvasive recurrence monitoring system for lung cancer.
Who can participate
Age range18 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
✓. Tumor tissue and blood samples obtainable at all protocol-specified time-points.
✓. No pure ground-glass nodule on imaging.
✓. Completed standard neoadjuvant immunotherapy combined with platinum-based chemotherapy.
Exclusion criteria
✕. Postoperative pathology shows other than NSCLC, including but not limited to benign lesions, small-cell carcinoma, metastasis, or indeterminate/inadequate histology.
✕. Insufficient or poor-quality blood or tissue samples.
✕. Pure ground-glass nodule on imaging.
✕. History of any malignancy within the past 5 years.
What they're measuring
1
Two-year recurrence-free survival rate
Timeframe: Time from curative surgery to confirmation of clinical progression (recurrence or metastasis) within two years